AstraZeneca Falls Today Even as Imfinzi Wins a Landmark Survival Test
Category: Financial
Share
Archive
Like
This article first appeared on GuruFocus.
AstraZeneca (NYSE:AZN), the oncology and biopharmaceutical company, reported a late-stage lung-cancer victory Tuesday, but investors refused to celebrate. Its U.S. shares fell approximately 0.7% to $161.51 even after Imfinzi, combined with Amgen's… This story appeared on finance.yahoo.com, 2026-09-08 16:35:42.
A note on cookies
Newshunt uses essential cookies to keep you signed in and to remember your language and country, so the site works the way you expect. With your permission, we'd also like to use analytics cookies to understand how people use Newshunt and improve it over time.
Accepting only affects analytics. To learn more, view our Privacy Policy or Terms & Conditions.
(0)Comments